Search

Alzheimer's disease is a neurodegenerative disorder that ultimately results from the accumulation of beta-amyloid plaques in the brain. The Alzheimer's disease cannot be prevented or cured at this time, and there is no recognised alternative. The medicinal solutions that are currently available can merely slow down its development. However, nanotechnology has demonstrated its applications in the medical field, and it demonstrates a great deal of promise in the treatment of Alzheimer's disease. In particular, it has shown significant promise in the detection of the condition and the development of an alternative technique to cure it. It is necessary for the medication delivery system to have the capability of penetrating and crossing the blood-brain barrier in order to accomplish this need. On the other hand, greater research is necessary in order to discover and overcome these limitations, which have the potential to improve drug absorption while simultaneously reducing toxicity and adverse effects. Certain nanotechnology-based techniques to treating Alzheimer's disease include regenerative medicine, neuroprotection, and stem cell regeneration. These are just few of the emerging approaches. This article's goal is to take a look at nanotechnology from every angle, including its advantages and disadvantages and how it's helping with neurodegenerative disease research and therapy.

Vernonia amygdalina is a small tree that can grow to a height of ten metres. It is sometimes referred to as bitter leaf due to the fact that its leaves have a bitter bitter flavour and its branches are frail. Although its natural habitat is in tropical Africa, it may be found all over the world in regions that receive an average rainfall of 750–2000 millimetres. These regions include areas that are adjacent to rivers and lakes, as well as forests and grasslands that are located up to an elevation of 2800 metres. The plant is mostly employed as a medicinal herb in the context of traditional medical practices. The plant contains a variety of phytoconstituents, the most important of which are phenol, oxalate, phytates, tannins, flavonoids, cyanogenic glycosides, alkaloids, terpenes, anthraquinone, steroids, coumarins, lignans, xanthones, edotides, sesquiterpenes, and phenol. There are a number of advantages associated with this plant, including its capacity to alleviate fever and pain, as well as its antidiabetic, anti-inflammatory, antioxidant, chemoprotective, and cytotoxic activities.

The SARS-CoV-2 virus, which causes COVID-19, initially emerged in Wuhan City, Hubei Province, China, in early December 2019. On January 30, 2020, the World Health Organisation proclaimed the pandemic a Public Health Emergency of International Concern. There have been 49,053 confirmed cases and 1,381 fatalities globally as of February 14, 2020. The risk of developing severe COVID-19 is increased in some congenital disorders, according to reported studies, because these conditions often come with pre-existing co-morbidities that impact the circulatory and respiratory systems, leading to potentially life-threatening pneumonia. A high risk for severe COVID-19 infection is not associated with congenital disorders other than those listed, even though they cause psychological discomfort in patients. A higher risk of developing new-onset diabetes among survivors was associated with COVID-19, according to this review. Glucose dysregulation must be closely monitored throughout the recovery process from SARS-CoV-2 infection. The SARS-CoV-2 virus has unleashed a COVID-19 pandemic that rivals the size of the 1918 flu pandemic. Although respiratory symptoms predominate, neurological symptoms are also being more acknowledged as a possible clinical manifestation. It is expected that SARS-CoV-2 will create many issues impacting the central nervous system or peripheral nervous system, based on what is known about previous coronaviruses like the ones that caused SARS and the Middle East respiratory syndrome outbreaks. Diabetes mellitus and arterial hypertension are risk factors for cardiovascular disease; the impact of COVID-19 on these conditions may not be fully recognised. Recent research suggests that a family history of COVID-19 infection may raise the risk of various cardiovascular diseases to a level comparable to those of established risk factors for this condition. Furthermore, the risk of developing CVD and the severity of its symptoms are both increased in patients wit

In December 2019, the source of the second severe acute respiratory syndrome coronavirus (SARS-CoV-2) was Wuhan City, Hubei Province, China. The disease caused by the SARS-CoV-2 coronavirus was officially named COVID-19 on February 11, 2020, by the World Health Organization (WHO). COVID-19 typically affects the lungs and causes a variety of symptoms, including fever, dry cough, and fatigue. The general public is at high risk of contracting SARS-CoV-2 because of how easily it can spread. Quick action has been taken by the Chinese government and scientific community to determine the source of the outbreak, communicate the viral gene sequence, and manage the pandemic. To find observational studies on COVID-19 risk estimations, this meta-analysis used PubMed, SciELO, and Web of Science data. Different data formats were utilized in the development of COVID-19 data search and collecting methods, including Emtree, meth words, and free text comprising phrases such as COVID-2019, SARS Cov-2, and MERS Cov-2. Clinical, demographic, medical, and epidemiological features were the primary foci of these approaches. The most susceptible hospital patient populations to contracting COVID-19 were determined by this meta-analysis study, which also detailed methods for preventing this illness. Coronavirus infection disease19 individuals' medication histories and illness risk assessments are the subjects of this meta-analysis.